Last reviewed · How we verify

TransThera Sciences (Nanjing), Inc. — Portfolio Competitive Intelligence Brief

TransThera Sciences (Nanjing), Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TT-00420 (tinengotinib) TT-00420 (tinengotinib) phase 3 Multi-targeted tyrosine kinase inhibitor VEGFR, FGFR, and other receptor tyrosine kinases Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Advenchen Laboratories Nanjing Ltd. · 1 shared drug class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
  3. Exelixis · 1 shared drug class
  4. GWT-TUD GmbH · 1 shared drug class
  5. H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
  6. Merck Sharp & Dohme LLC · 1 shared drug class
  7. National Cancer Institute, Naples · 1 shared drug class
  8. Sponsor GmbH · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TransThera Sciences (Nanjing), Inc.:

Cite this brief

Drug Landscape (2026). TransThera Sciences (Nanjing), Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/transthera-sciences-nanjing-inc. Accessed 2026-05-16.

Related